Listed Healthcare Companies Create Nearly 80,000 Jobs, Expanding Headcount by 48% Since 2019
A BTG Pactual survey shows ten listed healthcare companies increased their combined workforce from about 166,000…
B3 · Bovespa
HYPE3 Hypera
Profile
Financials
Related news on Hypera
Empresas listadas de saúde criam quase 80 mil empregos e ampliam quadro em 48% desde 2019
Levantamento mostra que dez empresas listadas do setor saíram de cerca de 166 mil para 245…
Hypera Pharma posts strong Q1 profit, revenue surge
Brazil’s Hypera Pharma (HYPE3.SA) reports 86.7% revenue jump and higher margins in Q1 2026, supported by…
Brazil’s 4Q25 earnings season looks weaker than it actually is
Excluding Petrobras, Vale and Braskem, earnings show stabilization — not deterioration — as revenue holds and…
Hypera confident in launching semaglutide in 2026
After patent expiry in March 2026, Hypera (HYPE3) aims to be among the first to sell…
Hypera Pharma posts R$453.9 million profit and record cash flow after working-capital overhaul
Net revenue rises 16%, EBITDA margin back to pre-optimization levels; company redeems costlier debt and reinforces…
Sanofi Advances Medley Sale, Plans Exit From Brazil Generics Market
Pharma executives in Brazil this week; Lazard advising, O Globo reports.
Brazilian drugmakers ready for Ozempic generic push
Anvisa to fast-track semaglutide generics; EMS, Hypera and Biomm eye 2026 rollout.
Hypera Cuts Targets, Focuses on Deleveraging and Bets on $6 Billion Ozempic Generic
Drugmaker trims 2025 outlook, focuses on cash generation as debt costs weigh; eyes multibillion-real opportunity in…
Market data by TradingView. Informational only — not investment advice.